source
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on companyA Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.STAT · 48m ago↗ source
- Novartis reports Phase 3 pelacarsen trial fails to improve cardiovascular outcomesNovartis said its late-stage Phase 3 trial of the antisense drug pelacarsen did not show a benefit in reducing major cardiovascular events compared with placebo. The result adds to a recent string…